1353278-46-2

Upstream product

• 1013-76-9 1-(2,4-dimethylphenyl)piperazine 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 1353279-01-2 3-amino-1-[{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-(p-methoxyphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353279-08-9 3-amino-1-[{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-phenyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-7-one 
• 1353279-14-7 3-amino-1-[3-{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-benzyl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 1353279-35-2 3-amino-1-[{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-{(furan-2-yl)methyl}-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-71-3 3-amino-1-[3-{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one 

Relevant academic research and scientific papers

Synthesis of 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7- one derivatives and evaluation of their anticancer activity

Promising anticancer compounds of the type 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-ones were identified. The target compounds were readily synthesized in a large scale via a sequence of reactions starting from the commercially available primary amines. Their in vitro anti-proliferative activity has been evaluated on prostate (DU-145), colon (HT-29 and HCT-116) and melanoma (A375P) human cancer cell lines. The relationships between the structure and the anticancer activity, covering all tested cancer cell lines, revealed that the compound 5c with 2,4-dimethylphenyl substituent at R2 was the most potent with the IC50 values in the range as low as 0.16 to 0.40 μM.

NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF

Provided are a novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound, a pharmaceutically acceptable salt compound thereof, a method for preparing the compound, and an anticancer pharmaceutical composition including the compound as an effective ingredient.